You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Trial of feasibility and acceptability of routine low-dose aspirin versus Early Screening Test indicated aspirin for pre-eclampsia prevention (TEST study): a multicentre randomised controlled trial
|
|---|---|
| Published in |
BMJ Open, July 2018
|
| DOI | 10.1136/bmjopen-2018-022056 |
| Pubmed ID | |
| Authors |
Fionnuala Mone, Cecilia Mulcahy, Peter McParland, Fionnuala Breathnach, Paul Downey, Dorothy McCormack, Marie Culliton, Alice Stanton, Fiona Cody, John J Morrison, Sean Daly, John Higgins, Amanda Cotter, Alyson Hunter, Elizabeth C Tully, Patrick Dicker, Zarko Alfirevic, Fergal D Malone, Fionnuala M McAuliffe |
| Abstract |
Evaluate the feasibility and acceptability of routine aspirin in low-risk women, compared with screening-test indicated aspirin for the prevention of pre-eclampsia and fetal growth restriction. Multicentre open-label feasibility randomised controlled trial. Two tertiary maternity hospitals in Dublin, Ireland. 546 low-risk nulliparous women completed the study. Women underwent computerised randomisation to: Group 1-routine aspirin 75 mg from 11 until 36 weeks; Group 2-no aspirin and; Group 3-aspirin based on the Fetal Medicine Foundation screening test. PRIMARY AND SECONDARY OUTCOME MEASURES: (1) Proportion agreeing to participate; (2) compliance with protocol; (3) proportion where first trimester uterine artery Doppler was obtainable and; (4) time taken to issue a screening result. Secondary outcomes included rates of pre-eclampsia and small-for-gestational-age fetuses. 546 were included in the routine aspirin (n=179), no aspirin (n=183) and screen and treat (n=184) groups. 546 of 1054 were approached (51.8%) and enrolled. Average aspirin adherence was 90%. The uterine artery Doppler was obtained in 98.4% (181/184) and the average time to obtain a screening result was 7.6 (0-26) days. Of those taking aspirin, vaginal spotting was greater; n=29 (15.1%), non-aspirin n=28 (7.9%), OR 2.1 (95% CI 1.2 to 3.6). Postpartum haemorrhage >500 mL was also greater; aspirin n=26 (13.5%), no aspirin n=20 (5.6%), OR 2.6 (95% CI 1.4 to 4.8). Low-risk nulliparous women are open to taking aspirin in pregnancy and had high levels of adherence. Aspirin use was associated with greater rates of vaginal bleeding. An appropriately powered randomised controlled trial is now required to address the efficacy and safety of universal low-dose aspirin in low-risk pregnancy compared with a screening approach. ISRCTN (15191778); Post-results. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 164 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 164 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 18 | 11% |
| Student > Master | 17 | 10% |
| Researcher | 14 | 9% |
| Other | 11 | 7% |
| Student > Postgraduate | 9 | 5% |
| Other | 29 | 18% |
| Unknown | 66 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 51 | 31% |
| Nursing and Health Professions | 23 | 14% |
| Biochemistry, Genetics and Molecular Biology | 5 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 2% |
| Immunology and Microbiology | 2 | 1% |
| Other | 12 | 7% |
| Unknown | 67 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 September 2023.
All research outputs
#1,704,698
of 25,385,509 outputs
Outputs from BMJ Open
#3,195
of 25,597 outputs
Outputs of similar age
#34,819
of 340,966 outputs
Outputs of similar age from BMJ Open
#92
of 591 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 25,597 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 340,966 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 591 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.